title: Randomized trial of pterygium surgery with mitomycin C application using conjunctival autograft versus conjunctival-limbal autograft.
abstract: OBJECTIVE
  To compare the outcomes of free conjunctival autograft (CAU) versus conjunctival-limbal autograft (CLAU) in the prevention of recurrence after pterygium surgery with adjunctive mitomycin C application in patients with primary or recurrent pterygia.
  
  
  METHODS
  Prospective, randomized study.
  
  
  METHODS
  Eighty-seven eyes of 86 patients with primary or recurrent nasal pterygia were included.
  
  
  METHODS
  All eyes underwent pterygium excision followed by removal of subconjunctival fibrovascular tissue and application of 0.02% mitomycin C for 3 minutes. The eyes then were assigned randomly to receive either CAU (44 eyes) or CLAU (43 eyes).
  
  
  METHODS
  Rate of conjunctival or corneal recurrence of pterygium after surgery.
  
  
  RESULTS
  A follow-up of at least 12 months (mean, 14 ± 2.2 months) was achieved in 78 eyes of 78 patients, including 39 eyes in the CAU group (31 primary and 8 recurrent pterygia) and 39 eyes in the CLAU group (33 primary and 6 recurrent pterygia). After surgery, no eye in the CLAU group developed pterygium recurrence; however, recurrence was seen in 2 eyes (5.1%) in the CAU group, including 1 of 31 patients (3.2%) with primary pterygia and 1 of 8 patients (12.5%) with recurrent pterygia. There was no statistically significant difference in recurrence rates between the 2 groups or in the primary and recurrent subgroups. In the CLAU group, a localized pannus formation at the donor site of the limbal graft was noted in 5 eyes (12.8%), with the appearance of pseudopterygium in 1 eye.
  
  
  CONCLUSIONS
  There was no significant difference in recurrence rates of pterygium after surgery with mitomycin C application between the CAU and CLAU groups, more remarkably in primary cases. Limbal damage was seen in some eyes with CLAU.
authors.affiliation: Farabi Eye Hospital, Eye Research Center, Tehran University of Medical Sciences, Tehran, Iran. Akheirkh@yahoo.com
authors.forename: Ahmad
authors.initials: A
authors.lastname: Kheirkhah
authors.forename: Hassan
authors.initials: H
authors.lastname: Hashemi
authors.forename: Mohsen
authors.initials: M
authors.lastname: Adelpour
authors.forename: Mojgan
authors.initials: M
authors.lastname: Nikdel
authors.forename: Mohammad Bagher
authors.initials: MB
authors.lastname: Rajabi
authors.forename: Mahmoud Jabbarvand
authors.initials: MJ
authors.lastname: Behrouz
mesh_terms: D000328:Adult; D000368:Aged; D000477:Alkylating Agents / Q000008:administration & dosage*; D017024:Chemotherapy, Adjuvant; D003228:Conjunctiva / Q000637:transplantation*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016850:Limbus Corneae / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage*; D011446:Prospective Studies; D011625:Pterygium / Q000145:classification / Q000473:pathology / Q000601:surgery*; D012008:Recurrence; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000477:Alkylating Agents; D016685:Mitomycin